WO2015019307A1 - Microcapsules contenant des probiotiques et leurs méthodes de fabrication - Google Patents
Microcapsules contenant des probiotiques et leurs méthodes de fabrication Download PDFInfo
- Publication number
- WO2015019307A1 WO2015019307A1 PCT/IB2014/063750 IB2014063750W WO2015019307A1 WO 2015019307 A1 WO2015019307 A1 WO 2015019307A1 IB 2014063750 W IB2014063750 W IB 2014063750W WO 2015019307 A1 WO2015019307 A1 WO 2015019307A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microcapsule
- probiotic
- microcapsules
- protein
- alginate
- Prior art date
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 128
- 239000006041 probiotic Substances 0.000 title claims abstract description 106
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title claims abstract description 26
- 229920000615 alginic acid Polymers 0.000 claims abstract description 90
- 229940072056 alginate Drugs 0.000 claims abstract description 89
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 74
- 230000000529 probiotic effect Effects 0.000 claims abstract description 70
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 64
- 229920001222 biopolymer Polymers 0.000 claims abstract description 41
- 235000019705 chickpea protein Nutrition 0.000 claims abstract description 28
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 27
- 239000000839 emulsion Substances 0.000 claims abstract description 26
- 239000000679 carrageenan Substances 0.000 claims abstract description 16
- 229920001525 carrageenan Polymers 0.000 claims abstract description 16
- 229940113118 carrageenan Drugs 0.000 claims abstract description 16
- 235000019722 synbiotics Nutrition 0.000 claims abstract description 16
- 229920002148 Gellan gum Polymers 0.000 claims abstract description 13
- 108010084695 Pea Proteins Proteins 0.000 claims abstract description 12
- 235000010492 gellan gum Nutrition 0.000 claims abstract description 12
- 239000000216 gellan gum Substances 0.000 claims abstract description 12
- 235000019702 pea protein Nutrition 0.000 claims abstract description 12
- 238000004132 cross linking Methods 0.000 claims abstract description 8
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 5
- 229940001941 soy protein Drugs 0.000 claims abstract description 5
- 230000002496 gastric effect Effects 0.000 claims description 23
- 230000000968 intestinal effect Effects 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 20
- 108010064851 Plant Proteins Proteins 0.000 claims description 18
- 210000000936 intestine Anatomy 0.000 claims description 18
- 235000021118 plant-derived protein Nutrition 0.000 claims description 18
- 239000008346 aqueous phase Substances 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 15
- 235000019198 oils Nutrition 0.000 claims description 15
- 241000186000 Bifidobacterium Species 0.000 claims description 12
- 241000186660 Lactobacillus Species 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 239000005017 polysaccharide Substances 0.000 claims description 10
- 239000004971 Cross linker Substances 0.000 claims description 9
- -1 hemicellulose Chemical class 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 239000007762 w/o emulsion Substances 0.000 claims description 6
- 102000016943 Muramidase Human genes 0.000 claims description 5
- 108010014251 Muramidase Proteins 0.000 claims description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 5
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 229960000274 lysozyme Drugs 0.000 claims description 5
- 235000010335 lysozyme Nutrition 0.000 claims description 5
- 239000004325 lysozyme Substances 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 229920001202 Inulin Polymers 0.000 claims description 4
- 108010019160 Pancreatin Proteins 0.000 claims description 4
- 210000000941 bile Anatomy 0.000 claims description 4
- 235000019519 canola oil Nutrition 0.000 claims description 4
- 239000000828 canola oil Substances 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 4
- 229940029339 inulin Drugs 0.000 claims description 4
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 4
- 229960000511 lactulose Drugs 0.000 claims description 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 4
- 230000007774 longterm Effects 0.000 claims description 4
- 229940055695 pancreatin Drugs 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- 241001608472 Bifidobacterium longum Species 0.000 claims description 3
- 229920002488 Hemicellulose Polymers 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 240000001929 Lactobacillus brevis Species 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 3
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 3
- 229920000294 Resistant starch Polymers 0.000 claims description 3
- 244000057717 Streptococcus lactis Species 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 235000015203 fruit juice Nutrition 0.000 claims description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 235000021140 nondigestible carbohydrates Nutrition 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 238000005453 pelletization Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 108010009004 proteose-peptone Proteins 0.000 claims description 3
- 235000021254 resistant starch Nutrition 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000011868 grain product Nutrition 0.000 claims description 2
- 235000013324 preserved food Nutrition 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 abstract description 30
- 102000004169 proteins and genes Human genes 0.000 abstract description 30
- 108090000623 proteins and genes Proteins 0.000 abstract description 30
- 241000196324 Embryophyta Species 0.000 abstract description 14
- 210000002784 stomach Anatomy 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 8
- 235000010418 carrageenan Nutrition 0.000 abstract description 4
- 210000003750 lower gastrointestinal tract Anatomy 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 77
- 210000004027 cell Anatomy 0.000 description 37
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 35
- 230000004083 survival effect Effects 0.000 description 25
- 244000045195 Cicer arietinum Species 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 18
- 235000010523 Cicer arietinum Nutrition 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 13
- 238000001878 scanning electron micrograph Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 235000010582 Pisum sativum Nutrition 0.000 description 11
- 240000004713 Pisum sativum Species 0.000 description 11
- 210000004051 gastric juice Anatomy 0.000 description 11
- 230000004224 protection Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 235000010469 Glycine max Nutrition 0.000 description 9
- 235000010749 Vicia faba Nutrition 0.000 description 9
- 240000006677 Vicia faba Species 0.000 description 9
- 235000002098 Vicia faba var. major Nutrition 0.000 description 9
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 235000019704 lentil protein Nutrition 0.000 description 7
- 150000004804 polysaccharides Chemical class 0.000 description 7
- 238000004626 scanning electron microscopy Methods 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910001424 calcium ion Inorganic materials 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000007963 capsule composition Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000219739 Lens Species 0.000 description 3
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229940071440 soy protein isolate Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical class O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 244000068687 Amelanchier alnifolia Species 0.000 description 1
- 235000009027 Amelanchier alnifolia Nutrition 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001596784 Pegasus Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000005072 Vigna sesquipedalis Nutrition 0.000 description 1
- 244000090207 Vigna sesquipedalis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical group O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000021278 navy bean Nutrition 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/14—Polymerisation; cross-linking
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/20—After-treatment of capsule walls, e.g. hardening
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/20—After-treatment of capsule walls, e.g. hardening
- B01J13/206—Hardening; drying
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/04—Reinforcing macromolecular compounds with loose or coherent fibrous material
- C08J5/0405—Reinforcing macromolecular compounds with loose or coherent fibrous material with inorganic fibres
- C08J5/042—Reinforcing macromolecular compounds with loose or coherent fibrous material with inorganic fibres with carbon fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2220/00—Biochemical treatment
- A23C2220/20—Treatment with microorganisms
- A23C2220/204—Use of bacteria which are encapsulated, entrapped or immobilised; Fermentation with these bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Definitions
- Some embodiments of the present invention pertain to microcapsules containing probiotics, probiotics and prebiotics, and/or synbiotics. Some embodiments of the present invention pertain to methods of making microcapsules containing probiotics, probiotics and prebiotics, and/or synbiotics.
- Probiotics are 'live microorganisms' or 'live microbial feed supplements' that offer health benefits to their host, and include primarily bacteria from the Lactobacillus and
- Beneficial effects on the host are thought to include: promoting digestion and mineral absorption; maintaining intestinal microbial balance; improving immune system response and resistance to pathogens; preventing intestinal tract infection; reducing the risk of cardiovascular disease, cancer, obesity and type-2 diabetes; regulating lipid levels and serum cholesterol; ameliorating lactose intolerance; as well as treating certain symptoms, such as inflammation, autoimmune responses, or allergies (Gibson & Roberfroid, 1995; Collins & Gibson, 1999; Shortt, 1999; Hooper et al., 2001; Pridmore et al., 2004; Sartor, 2004; Bielecka, 2007; Rastall, 2007; Sarkar, 2007).
- Bifidobacteria are non-motile, non-spore forming and strictly anaerobic Gram-positive bacteria that grow at pH values between 4.5 and 8.5 (Scardovi, 1986; Rokka and Rantamaki, 2010). They are indigenous to the human intestine (Fuller, 1991) and play an important beneficial role in inhibiting proliferation of potentially harmful microorganisms in the gastrointestinal tract (Hoover, 1993; Gibson & Roberfroid, 1995; Yaeshima, 1996; Holzapfel, Haberer, Snel, Schillinger, & Huis in't Veld, 1998; Alander et al., 1999).
- Bifidobacteria species include Bifidobacteria adolescentis, Bifidobactertium animalis,
- Lactobacilli are large, non-spore forming, Gram-positive rods, that have anaerobic or microaerophilic respiration. Gram-positive bacteria have a thick peptidoglycan layer as part of their cell wall whereas Gram-negative bacteria have a thin layer. Anaerobic bacteria will not grow in the presence of oxygen and therefore an atmosphere devoid of oxygen must be present in order for their growth to occur. Microaerophilic organisms are organisms that require a lower concentration of oxygen than that found in air.
- Lactobacillus bacteria are microaerophilic and are commonly used as a starter culture in yogurt production and are the most commonly used probiotics in foods.
- Exemplary Lactobacillus species used as probiotics include L. delbreuckii subspecies bulgaricus, L. acidophilus, L. casei, L. germentum, L. plantarum, L. brevis, L.
- Prebiotics are compounds that support probiotic growth. Prebiotics act to increase the number and activity of beneficial bacteria which already colonize the colon.
- Exemplary prebiotics include non-digestible carbohydrates such as: resistant starch (starch which is not hydrolysed in the small intestine), non-starch polysaccharides (hemicellulose, pectins, gums), and oligosaccharides (galactooligosaccharides, fructoligosaccharides, maltoligosaccharides), lactulose, inulin, and the like.
- Synbiotics are nutritional supplements containing both probiotics and prebiotics. In some cases the combination of prebiotics and probiotics produces synergistic health benefits, hence the term “synbiotics” is used.
- probiotic strains are sensitive to the harsh environmental conditions within foods, during processing and during transit through the gastrointestinal tract (Charteris, Kelly, Morelli, & Collins, 1998; Clark & Martin, 1994; Truelstrup Hansen, Allan- Wojtas, Jin, & Paulson, 2002).
- GI lower gastrointestinal
- encapsulation technology may be used to deliver therapeutic levels of both prebiotics and probiotics to the GI system, providing maximum health benefits of these agents.
- Encapsulation technology involves encasing the sensitive core ingredients within a biopolymer shell, which can release its contents at controlled rates once triggered by an external sensor (e.g., temperature, pH, enzymes, etc.).
- an external sensor e.g., temperature, pH, enzymes, etc.
- alginate-based capsules seem to dominate.
- Alginate is a linear heteropolysaccharide comprised of D-mannuronic and L-guluronic acids; the latter being highly- sensitive to divalent calcium ions resulting in the formation of strong egg box-like junction zones.
- past alginate-probiotic capsules have been shown to be ineffective at adequately protecting probiotic bacteria subjected to simulated gastric juice.
- small capsules ( ⁇ 100 ⁇ ) can be produced using an emulsification technique, allowing capsules to be incorporated into foods without affecting their sensory attributes (Cui, Goh, Kim, Choi, & Lee, 2000; Lee & Heo, 2000; Truelstrup Hansen et al., 2002; Chandramouli, Kailasapathy, Peiris, & Jones, 2004).
- Plant proteins are becoming increasingly important to the food industry as a replacement for animal-derived proteins (e.g., gelatin and whey) for use as food and encapsulating ingredients.
- Plant proteins represent an attractive alternative because of their low cost, renewability and functionality and as replacements for animal proteins based on consumer choices (e.g., vegans) and religious practices. They also are advantageous when used in combination with polysaccharides as wall materials, as they can be designed to have pH- or enzymatic triggers for controlled release purposes.
- the application of plant proteins as encapsulating agents for probiotic delivery is currently very limited; however, this practice could be developed for use in non-dairy markets and products. Klemmer, Korber, Low, and Nickerson (2011) recently determined that pea protein isolate-alginate mixed capsules prepared by extrusion offered significant protection to B. adolescentis within simulated gastric juice (SGJ) over 2 h/37°C, and showed prolonged release within simulated intestinal fluids (SIF). However, capsule sizes were too large ( ⁇ 2 mm) for use as food supplements.
- SGJ gastric juice
- SIF simulated intestinal fluids
- microcapsules having a smaller particle size acceptable for incorporation into food products that does not adversely affect the sensory attributes of the food product (i.e. less than about 100 ⁇ diameter).
- Microcapsules having a smaller particle size have a greater surface area to volume ratio, leading to increased exposure to surface area and decreasing the survival of probiotics.
- Polysaccharide-based microcapsules can be made, but provide poor survival rates for probiotics.
- a microcapsule for protecting a probiotic and/or delivering a probiotic to an intestine of a subject comprises a biopolymer, a plant protein and a probiotic, and the microcapsule is prepared by crosslinking the biopolymer in an emulsion of the biopolymer, the plant protein, the probiotic, and an oil to encapsulate the probiotic.
- a method of preparing a microcapsule includes combining a plant protein, a biopolymer and a probiotic to form an aqueous phase, adding an oil to the aqueous phase to form an emulsion, adding a crosslinker to crosslink the biopolymer, and separating the microcapsules from the oil phase of the emulsion.
- the plant protein is chickpea protein isolate, pea protein isolate, and/or soy protein isolate.
- the biopolymer is alginate, iota-carrageenan, and/or deacylated gellan gum.
- the probiotic is from the Lactobacillus or Bifidobacterium genera. In some embodiments, the probiotic is encapsulated together with a prebiotic.
- the microcapsules have a diameter of between about 20 and about 100 micrometers. In some embodiments, the microcapsules are incorporated into a food product. In some embodiments, the food product is yogurt, fruit juice, a cereal product, or a dried food product. In some embodiments, the microcapsule provides delivery of the encapsulated probiotic to the intestine of a mammalian subject.
- Figure 4 shows the survival of B. adolescentis entrapped in alginate microcapsules incorporating different plant-based proteins (pea, soy, faba, and lentil) as a function of time within synthetic gastric juice.
- Figure 5 shows the release of B. adolescentis entrapped in alginate microcapsules incorporating different plant-based proteins (pea, soy, faba, and lentil) as a function of time within simulated intestinal fluid.
- Figure 8A shows an SEM (scanning electron microscopy) image of a microcapsule prepared from chickpea protein isolate and alginate at 625x magnification.
- Figure 8B shows an SEM image of a microcapsule prepared from chickpea protein isolate and alginate at 2500x magnification.
- Figure 9A shows an SEM image of a microcapsule prepared from pea protein isolate and alginate at 625x magnification.
- Figure 9B shows an SEM image of a microcapsule prepared from pea protein isolate and alginate at 2500x magnification.
- Figure 10A shows an SEM image of a microcapsule prepared from soy protein isolate and alginate at 625x magnification.
- Figure 10B shows an SEM image of a microcapsule prepared from soy protein isolate and alginate at 2500x magnification.
- Figure 11 A shows an SEM image of a microcapsule prepared from faba bean protein isolate and alginate at 625x magnification.
- Figure 11B shows an SEM image of a microcapsule prepared from faba bean protein isolate and alginate at 2500x magnification.
- Figure 12A shows an SEM image of a microcapsule prepared from lentil protein isolate and alginate at 625x magnification.
- Figure 11B shows an SEM image of a microcapsule prepared from lentil protein isolate and alginate at 2500x magnification.
- Some embodiments of the present invention pertain to micron- sized plant protein-based capsules for carrying probiotic bacteria, and/or mixtures of prebiotics and probiotic bacteria, and/or probiotic-prebiotic synbiotics.
- the capsules can protect the probiotic bacteria against conditions of the stomach (e.g. gastric pH) and facilitate targeted delivery of the probiotic bacteria to the intestines of a mammalian subject.
- conditions of the stomach e.g. gastric pH
- the capsules are suitable for use as a food ingredient, being sufficiently small in size to avoid adverse effects on a tongue of a subject.
- the capsules are used as nutritional supplements or ingredients in human food products and/or animal feed.
- Gastric conditions are conditions similar to the conditions that would be experienced by a microcapsule in the stomach of a mammal. In some embodiments, the gastric conditions are similar to the conditions that would be experienced by a microcapsule in the stomach of a human. In some embodiments, "gastric conditions” that would be experienced in the stomach of a mammal means a pH of about 1.5-4.1 and a temperature of between about 36.5°C and 39.5°C. In some embodiments, gastric conditions comprise approximately 0.5% HC1 with large quantities of KCl and NaCl (Kararli, 1995).
- gastric conditions that would be experienced in the stomach of a human means a pH of about 1.5 to 3.5 and a temperature of between about 36.5°C and about 37.5°C.
- gastric conditions includes the presence of other compounds such as enzymes such as lysozyme and pepsin.
- intestinal conditions are conditions similar to those that would be experienced by a microcapsule in the small intestine of a mammal.
- the intestinal conditions are similar to those that would be experienced by a microcapsule in the small intestine of a human.
- intestinal conditions that would be experienced in the small intestine of a mammal means a pH in the range of approximately 5.0-8.0 and a temperature of about 36.5°C to 39.5°C.
- intestinal conditions that would be experienced in the small intestine of a human means a pH in the range of 5.0 to 7.0 and a temperature of about 36.5°C to 37.5°C.
- intestinal conditions includes the presence of other compounds such as bile and enzymes such as pancreatin (a mixture of amylase, lipases and proteases).
- microcapsules made from a biopolymer and a plant-based protein.
- the microcapsules are used to contain a probiotic, a probiotic and a prebiotic, or a synbiotic.
- the microcapsules can be used to deliver a probiotic to an intestine of a mammalian subject by protecting the probiotic from the conditions prevailing in the stomach of the subject and releasing the probiotic under the conditions experienced in the intestine of the subject.
- the microcapsules can be used to deliver a probiotic and a prebiotic, or a synbiotic, to an intestine of a mammalian subject by protecting the probiotic and prebiotic, or synbiotic, from the conditions prevailing in the stomach of the subject and releasing the probiotic under the conditions experienced in the intestine of the subject.
- the biopolymer is alginate.
- the biopolymer is iota-carrageenan.
- the biopolymer is deacylated gellan gum.
- the biopolymer is present in the initial aqueous phase prior to emulsion at a concentration of between about 0.05 and 0.50% w/v or any value therebetween, e.g. 0.07, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40 or 0.45% w/v in the initial aqueous phase prior to emulsion.
- a higher concentration of biopolymer is used where there is a higher concentration of protein present.
- the plant-based proteins are chick pea protein, pea protein and/or soy protein.
- the plant-based protein is present at a concentration of between about 5 and 10% w/w in the initial aqueous phase prior to emulsion, or any value therebetween, e.g. about 6, 7, 8 or 9% w/w in the initial aqueous phase prior to emulsion. In some embodiments, the plant-based protein is present at a concentration of 10% w/w in the initial aqueous phase prior to emulsion. Higher concentrations of plant-based protein could potentially be used if desired, but sufficiently high concentrations of plant-based protein could lead to solubility and/or viscosity issues.
- the biopolymer is crosslinked to provide the microcapsules.
- suitable crosslinkers include calcium (e.g. supplied as CaCl 2 ), or magnesium (e.g. supplied as MgCl 2 ).
- an excess of crosslinker is added to the water-in-oil emulsion to cross-link the biopolymer.
- the crosslinker is present in a concentration in the range of about 0.1 to 0.5 M in the water-in-oil emulsion or any value therebetween, e.g. 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, or 0.45 M in the water-in-oil emulsion.
- Some embodiments provide micron-sized plant protein-based microcapsules capable of carrying probiotic bacteria, mixtures of probiotic and prebiotics, or synbiotics through conditions of gastric pH to provide targeted delivery of the contents of the capsules within the intestines of a mammalian subject.
- the capsules are less than approximately 100 micrometers in diameter, less than approximately 20 micrometers in diameter, or any value therebetween, e.g. less than approximately 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35 or 30 micrometers in diameter.
- the capsules are between about 20 and about 100 micrometers in diameter.
- the capsules are useful as feed and food supplements or ingredients.
- the encapsulated probiotic is from the Lactobacillus or
- the probiotic is Bifidobacteria adolescentis, Bifidobactertium animalis, Bifidobacterium bifidum, Bifidobacterium breve or Bifidobacterium longum.
- the probiotic is Lactobacillus delbreuckii subspecies bulgaricus, L. acidophilus, L. casei, L. germentum, L. plantarum, L. brevis, L. cellobious, L. lactis or L. reuteri.
- the encapsulated probiotic is a combination of one or more of the preceding species.
- the probiotic is Bifidobacteria adolescentis.
- the encapsulated prebiotic is a carbohydrate. In some embodiments, the encapsulated prebiotic is a carbohydrate. In some
- the encapsulated prebiotic is a non-digestible carbohydrate such as: resistant starch (starch which is not hydrolysed in the small intestine); a non-starch polysaccharide such as hemicellulose, pectins, or gums; an oligosaccharide such as a galactooligosaccharide, fructoligosaccharide, maltoligosaccharide; lactulose; inulin; or the like.
- the encapsulated prebiotic is a fructooligo saccharide, lactulose, transgalactooligosaccharide, or inulin.
- the encapsulated probiotic is combined with a suitable prebiotic to provide a synbiotic.
- the microcapsules protect the encapsulated probiotic from conditions experienced during the processing and storage of a feed product such as animal feed. In some embodiments, the microcapsules protect the encapsulated probiotic from conditions experienced during pelletization of the feed product. In some embodiments, the microcapsules protect the encapsulated probiotic to retain viability of the probiotic during long term storage of the feed product, for example for a period of time greater than two weeks to six months or more, or any period of time there between, e.g. four weeks, six weeks, eight weeks, ten weeks, three months, four months, five months, or the like.
- the microcapsules protect the encapsulated probiotic from conditions experienced during preparation and/or storage of a food product, for example, low pH, extrusion, drying or the like.
- food products in which the microcapsules according to embodiments of the present invention might be used include dairy products (e.g. yogurt having a pH in the range of about 3.5 to 4.0), cereals, dried fruit products, and/or fruit juices having moderately low pH.
- the capsules are prepared using an emulsion technique that involves dispersing a mixture of the plant-based protein, the biopolymer and the probiotic as droplets within a continuous oil medium to create an emulsion.
- the emulsion is formed in a vegetable oil.
- the emulsion is formed in canola oil.
- the emulsion is broken using a solution of cross-linker (to cross-link the biopolymer), followed by a hardening step. Microcapsules are then hardened and harvested.
- the microcapsules are dried after being harvested. Any suitable drying method that is compatible with the encapsulated probiotic can be used to dry the microcapsules. In some embodiments, drying of the microcapsules is done by freeze-drying.
- the microcapsules provide protection against substantial loss of viability of the probiotic contained in the microcapsules for at least two hours under simulated gastric conditions.
- substantially loss of viability means any loss of viability greater than about 2 log CFU/g.
- the microcapsules provide protection against a loss of viability greater than about 1 log CFU/g.
- the microcapsules provide protection against a loss of viability greater than about 3 log CFU/g.
- the microcapsules provide release of the probiotic contained in the microcapsules under simulated intestinal conditions.
- the probiotics contained in the microcapsules may provide a positive influence on the gastrointestinal system of a mammalian subject, even in cases where the probiotics are not delivered live to the small intestine of the subject.
- microcapsules can be used to provide targeted delivery of the encapsulated probiotic or combination of probiotic and prebiotic, or synbiotic, to the intestines of a
- mammalian subject by protecting the encapsulated material against a substantial loss of viability due to gastric conditions during transit through the stomach of a mammalian subject, and then releasing the encapsulated material upon exposure to intestinal conditions in the intestine of the mammalian subject.
- the microcapsules are used to deliver a probiotic, probiotic and prebiotic, or synbiotic to the intestine of a mammalian subject.
- the microcapsules are stable at gastric pH to protect the probiotic from degradation in the stomach of the mammalian subject, as can be observed by the extended survival of prebiotics under simulated gastric conditions.
- the microcapsules release the probiotic, probiotic and prebiotic, or synbiotic in the intestine of the mammalian subject under intestinal conditions.
- the microcapsules are prepared by forming a water-in-oil emulsion in a solution containing the plant-based protein, the biopolymer, and the material to be encapsulated. The mixture is mixed to achieve homogeneity and is then added to oil.
- the oil is a vegetable oil such as canola oil. The resulting mixture is stirred.
- a crosslinking agent is added.
- the crosslinking agent is calcium chloride or magnesium chloride.
- the aqueous phase containing the microcapsules is separated from the oil phase.
- the microcapsules are rinsed with a suitable detergent to maintain good capsule dispersability after the microcapsules have been separated from the oil phase.
- the microcapsules are dried in any suitable manner, for example, by freeze- drying.
- Alginic acid sodium salt from brown algae, ⁇ -carrageenan, L-cysteine hydrochloride monohydrate, proteose peptone, bile salt, pepsin from porcine gastric mucosa, lysozyme from egg white, pancreatin from porcine pancreas, and TweenTM 80 (polysorbate 80) were all supplied from Sigma-Aldrich (Mississauga, ON, Canada); De man, Rogosa, Sharpe (Lactobacilli MRS). Broth, calcium chloride (CaCl 2 ), sodium bicarbonate (NaHC0 3 ) and sodium chloride (NaCl) were purchased from EMD Chemicals Inc.
- Chickpea seeds kindly donated by the Crop Development Centre (Saskatoon, SK), were initially ground using a bowl grinder (Cuisinart Mini-Prep Plus) followed by a fine grind (IKA Al l basic. IKA Works Inc., Wilmington, NC) to give flour.
- the flour was then defatted with hexane (L'Hocine, Boye, & Arcand, 2006) and then concentrated utilizing an isoelectric precipitation procedure (Can Karaca et al., 201 la).
- the defatted flour was dispersed in MQW at a 1 to 10 (w/v) protein/MQW ratio, followed by pH adjustment to 9.0 with 1.0 M NaOH so as to facilitate protein solubility.
- the resulting solution was stirred at 1000 rpm
- the crude ash, lipid, moisture and protein (%N x 6.25) contents for the resulting isolate was determined according to the Association of Official Analytical Chemists (AOAC, 2003) methods: 923.03, 920.85, 925.10, and 920.87, respectively.
- the carbohydrate content was determined on the basis of percent differential from 100%. Chemical analysis of the isolate indicated protein, moisture, lipid, ash and carbohydrate levels were 85.76%, 2.39%, 0.83%; 4.41% and 6.89%, respectively.
- Bifidobacterium adolescentis (ATCC 15703) was stored at -70°C in a 1/1 (v/v) suspension of 15% (w/v) glycerol and 5.22% (w/v) MRS broth. Cultures were streaked onto RCM agar supplemented with 0.05% (v/v) L-cysteine HC1 (RCM-cys) plates at 37°C under anaerobic conditions (80% N 2 , 10% C0 2 and 10% H 2 ) in an anaerobic chamber (Forma
- a total of 10.0 mL of 5.22% (w/v) MRS broth supplemented with 0.05% (w/v) L- cysteine-HCl and 1.5% (w/v) agar was inoculated with two isolated colonies of B. adolescentis for 20 hours at 37 °C under anaerobic conditions. After centrifugation for 5 minutes at 1000 x g, the resulting pellet was re-suspended in 1.00 mL of sterile 0.1% (w/v) alkaline peptone water (APW). Probiotics were then applied to encapsulation study and the final concentration (log CFU mL "1 ) of probiotics grown under anaerobic conditions at 37°C for 48 hours was determined through the spread plate count method conducted in duplicate.
- Microcapsules were prepared with the chickpea protein isolates using emulsion-based technology which employed a two-phase system to make a water-in-oil emulsion (Truelstrup Hansen et al, 2002; Butler, Ng, & Pudney, 2003; Krasaekoopt, Bhandari, & Deeth, 2003; Winder et al., 2003).
- niL of a chickpea protein (1.18 g protein power containing 1.00 g protein) solution (10% (w/w) with respect to the final volume of the aqueous phase, 10.0 mL) was prepared in MQW, adjusted to pH 7.0 with 0.5 M NaOH, and stirred at room temperature overnight (16 hours).
- Genipin, alginate or ⁇ -carrageenan powder was added to the solution to reach a final concentration of 0.2% (w/v).
- Genipin and alginate powder could be added directly to the solution; however, in the case of ⁇ -carrageenan, the powder was dissolved first at 60°C in advance and then cooled to room temperature before use.
- One mL of bacterial suspension was subsequently added to the protein-crosslinker mixture to bring the final volume of the aqueous wall material solution to 10.0 mL.
- the mixture was stirred (750 rpm) for 5 minutes to achieve homogeneity and then added into 100.00 g of canola oil, and the resulting mixture was stirred with an overhead Real Torque Digital Stirrer (Caframo, Wiarton, ON, Canada) at 1000 rpm.
- an overhead Real Torque Digital Stirrer (Caframo, Wiarton, ON, Canada) at 1000 rpm.
- the emulsion was stirred for 6 hours so as to afford time for crosslinking, followed by the addition of 100.00 g of MQW to break the emulsion in order to harvest the microcapsules.
- emulsions were stirred for 0.5 hours, followed by the addition of 100.00 g of 0.1 M CaCl 2 and 0.3 M KC1, respectively, to facilitate microcapsule formation via ionic crosslinking.
- the resulting suspension was then centrifuged for 5 minutes at 1000 x g to fully separate the oil phase from the capsule-aqueous phase.
- the aqueous phase was rinsed with 10.0 mL of a 1.0% TweenTM 80 (polysorbate 80) solution so as to maintain good capsule dispersability.
- the aqueous capsule phase was then transferred to a 50 mL separatory funnel and allowed to settle for 5 minutes prior to the final capsule harvest to ensure full removal of the oil phase.
- the concentration of viable encapsulated organisms (CFU mL "1 ) was then determined by plate counting on MRS-cys agar plates.
- Microcapsules were prepared using pea, soy, faba bean and lentil protein isolate in the same manner as described above, with the alternate protein being substituted for chickpea protein isolate.
- Microcapsules were prepared using pea protein-iota carrageenan and pea protein-deacyl gellan gum mixtures in the same manner as described above, with the alternate biopolymer being substituted for alginate.
- Example 1.5 Capsule Size
- Capsule size was determined by light scattering using a Mastersizer 2000 equipped with a Hydro 2000S wet sample cell (Malvern Instruments, Westborough, MA, USA). Measurement conditions used in the Mastersizer included % obscurity (10 - 20%), a pump speed of 850 rpm, a sample absorbance default of 0.1 and refractive index values of 1.45 and 1.33 for the sample (protein) and dispersant (MQW), respectively. Experiments were performed using each capsule formulation for duplicate batches, with size analysis completed in duplicate.
- SGJ was prepared with a total of 8.3 g of proteose peptone, 3.5 g of glucose, 2.05 g of NaCl, 0.6 g of KH 2 P0 4 , 0.11 g of CaCl 2 , 0.37 g of KC1, 0.05 g of bile, 0.1 g of lysozyme, and 13.3 mg of pepsin in 1 L of MQW with adjustment to pH 2.5 by 1 M HC1. SGJ was heated to 37°C for 30 min and sterile filtered before use. The ability of free and encapsulated B.
- Chickpea protein-alginate capsules were produced and harvested as previously described. The free cell and the entrapped probiotics in chickpea- alginate capsules were re- suspended with 2.0 mL of 0.1% APW, and then incubated in 48.0 mL of SGJ with stirring (750 rpm) for 2 hours under anaerobic conditions at 37°C. Sampling was carried out at 10, 30, 60, and 120 minutes.
- a 100 ⁇ ⁇ aliquot was sampled and serially diluted in 900 ⁇ ⁇ sterile 0.1% APW to relieve SGJ stress.
- the first dilution of each sample was homogenized (Omni International Inc., GA, USA) at 13,000 rpm for 30 seconds to break up the capsule wall.
- the number of viable surviving bacteria (log CFU mL "1 ) was determined by plate counting after 48 hours anaerobic incubation at 37°C for each time tested. Replicate plates were counted at each time interval during the survival study, and then repeated in duplicate.
- the free cell and entrapped probiotics in chickpea- alginate capsules were re-suspended with 2 mL of 0.1% APW, and then added into 48.0 mL SIF, pH 6.5 (adjusted with 0.1 M NaOH), with stirring (750 rpm) for 3 hours under anaerobic conditions at 37°C. Sampling was carried out at 10, 30, 60, 120, and 180 minutes. The diluted samples were directly incubated without mechanical homogenization to break the capsules. The number of viable surviving bacteria (log CFU mL "1 ) was determined by plate counting after 48 hours anaerobic incubation at 37°C for each time tested. Replicate plates were counted at each time interval during the release study, and repeated in duplicate.
- Bifidobacterium adolescentis was entrapped within a 10.00% (w/w) chickpea protein capsule crosslinked with (0.20% w/v) genipin or in the presence of (0.20% w/v) alginate or ⁇ - carrageenan. Overall, the entrapment process did not significantly suppress the growth of B. adolescentis regardless of the capsule formulation (p>0.05). Prior to encapsulation, the number of viable B.
- adolescentis was 8.6 + 0.1 log CFU mL "1 , whereas afterwards cell counts ranged between 8.5 + 0.1 and 8.7 + 0.1 log CFU mL "1 for the protein capsules with alginate or ⁇ - carrageenan, respectively.
- viable cell counts were reduced to 7.8 + 0.1 log CFU mL "1 .
- Figure 1 shows viable log CFU mL "1 over a 2 hour acid challenge (pH 2.0/25°C) for encapsulated and free cells, and free cells with genipin. Viable cell counts after 2 hours were significantly reduced in all capsule formulations relative to time zero (p ⁇ 0.01), as well as amongst themselves (p ⁇ 0.01).
- Chickpea protein- alginate capsules offered the greatest protection to B. adolescentis (4.6 + 0.1 log CFU mL "1 ), followed by chickpea protein capsules prepared with K-carrageenan (3.5 + 0.3 log CFU mL "1 ) and genipin (1.8 + 0.1 log CFU mL "1 ) ( Figure 1).
- the majority of free cells died within the first 30-90 minutes of exposure to pH 2.0/25°C following a similar trend as the encapsulated CPI-alginate/ ⁇ - carrageenan ( Figure 1).
- Viable cells within the CPI-genipin capsule showed the majority of losses within the first 30-40 minutes, below that of free cells alone.
- chickpea protein-alginate capsules appeared to offer better survival at pH 2.0/25°C than the other formulations and is of a more appropriate size ( ⁇ 100 ⁇ ) size.
- the high surface area to volume ratio can potentially lead to reduced survival under simulated gastric conditions (Sultana et al., 2000).
- Example 2.2 Chickpea Protein- Alginate Capsules: The Effect of Alginate Concentration on the Survival of B. adolescentis During an Acid Challenge
- Table 1 shows changes to viable cell counts for the different formulations and loss reductions over a 2 hour period at pH 2.0/25°C. After 2 hours, all capsule formulations were found to be significantly lower than time zero (p ⁇ 0.01) and also different amongst themselves (p ⁇ 0.01). The greatest protection was found for capsules prepared with 0.10% (w/v) alginate (0.6 + 0.3 log CFU mL "1 reduction), followed by 0.05% (w/v) (1.5 + 0.2 log CFU mL "1 reduction) and then 0.20% (w/v) (2.8 + 0.4 log CFU mL "1 reduction) (Table 1).
- Viable cells (log CFU mL 1 )
- Alginate capsules (0.10% w/v) without chickpea protein were also prepared and subjected to the same acid challenge, to show a 3.7 + 0.7 log CFU mL "1 cell number reduction over the 2 hour period (Table 1), which is significantly greater than when chickpea protein was present (p ⁇ 0.05).
- Table 1 Alginate capsules (0.10% w/v) without chickpea protein was also prepared and subjected to the same acid challenge, to show a 3.7 + 0.7 log CFU mL "1 cell number reduction over the 2 hour period (Table 1), which is significantly greater than when chickpea protein was present (p ⁇ 0.05).
- an alginate-Ca network developed to maintain capsule integrity, with the globular chickpea proteins packed within interstitial spaces acting to fill pores within the capsule.
- Alginate is a linear polysaccharide comprised of L-guluronic and D-mannuronic acid residues as homo- or co-block polymeric regions.
- the present examples demonstrate the potential for entrapping probiotics within a chickpea protein-based capsule, either crosslinked by genipin or in the presence of alginate or ⁇ - carrageenan (plus salts).
- a chickpea protein capsule in the presence of 0.10% (w/v) alginate offered the best protection under the tested conditions to B. adolescentis within synthetic gastric juice.
- Capsules produced using this design were ⁇ 100 ⁇ in size, and as such, there would be no perceived adverse effects on the sensory attributes of this ingredient into foods by consumers.
- Within simulated intestinal fluid a burst-release of B.
- chickpea protein- alginate microcapsule designs could serve as a suitable probiotic carrier intended for food applications to provide targeted delivery of a probiotic to the intestines of a mammalian subject, including a human subject.
- Figure 4 shows the protection of B. adolescentis from simulated gastric conditions by the alginate microcapsules with pea, soy, faba bean or lentil protein.
- Figure 5 shows the release of B. adolescentis from the microcapsules under simulated intestinal conditions.
- microcapsules made from a combination of alginate and pea protein or alginate and soy protein provide strong protection to an encapsulated probiotic under simulated gastric conditions, while allowing release of the encapsulated probiotic under simulated intestinal fluid.
- microcapsules made from a combination of alginate and pea protein or alginate and soy protein will be able to provide targeted delivery of a probiotic through the stomach of a mammalian subject to its intestine.
- Microcapsules were prepared using pea protein-iota carrageenan (P-I) and pea protein- deacyl gellan gum (P-D) mixtures to determine if either polysaccharide could be used instead of alginate.
- P-I pea protein-iota carrageenan
- P-D pea protein- deacyl gellan gum
- microcapsules prepared using iota-carrageenan or deacyl gellan gum as the biopolymer can provide protection to probiotics under simulated gastric conditions while allowing release under simulated intestinal conditions. It can therefore be soundly predicted that iota-carrageenan and deacyl gellan gum can be used as the biopolymer in some embodiments of the present invention to provide targeted delivery of probiotics, probiotics and prebiotics, and/or synbiotics to the intestine of a mammalian subject, including a human subject.
- SEM images were obtained using microcapsules prepared from different plant proteins (chickpea, pea, soy, faba bean or lentil protein) in conjunction with alginate polysaccharide. SEM images indicated that the microcapsules formed using chickpea or pea protein were more distinct and spherical ( Figures 8A/8B and 9A/9B). In contrast, microcapsules formed using soy, faba bean or lentil protein isolate formed using alginate appeared more as a aggregated mass rather than a distinct capsule ( Figures 10A/10B, 11 A/1 IB and 12A/12B), and was less-effective at protecting the probiotic bacteria during acid challenge experiments.
- Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract Journal of Applied Microbiology, 84, 759-768. Clark, P. A., & Martin, J. H. (1994). Selection of bifidobacteria for use as dietary adjuncts in cultured dairy foods: III- Tolerance to simulated bile concentrations of human small intestines. Cultured Dairy Products Journal, 29, 18-21.
- probiotic survial, adherence and antimicrobial resistence candidate selection for encapsulation in a pre proein isolate-alginate delivery system.
- Gastrointestinal microbes increase arsenic bioaccessibility of ingested mine tailings using the simulator of the human intestinal microbial ecosystem.
- Microencapsulation a strategy for formulation of inoculum. Biocontrol Science and
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des microcapsules de protection de probiotiques et leurs méthodes de fabrication. Selon certains modes de réalisation, les microcapsules sont utilisées pour obtenir une délivrance de probiotiques, de combinaisons de probiotiques et de prébiotiques, et/ou de symbiotiques à travers l'estomac d'un mammifère jusqu'à son tube digestif inférieur. Selon certains modes de réalisation, les microcapsules comprennent un biopolymère et une protéine à base de plante. Selon certains modes de réalisation, les microcapsules comprennent un alginate, du carraghénane iota ou une gomme gellane désacylée, en tant que biopolymère. Selon certains modes de réalisation, les microcapsules comprennent des protéines de pois chiches, des protéines de pois ou des protéines de soja en tant que protéines à base de plante. Une émulsion contenant le biopolymère, la protéine à base de plante et la matière probiotique à encapsuler peut être soumise à une réticulation pour former la microcapsule.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361863264P | 2013-08-07 | 2013-08-07 | |
US61/863,264 | 2013-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015019307A1 true WO2015019307A1 (fr) | 2015-02-12 |
Family
ID=52460734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/063750 WO2015019307A1 (fr) | 2013-08-07 | 2014-08-06 | Microcapsules contenant des probiotiques et leurs méthodes de fabrication |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015019307A1 (fr) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016065279A1 (fr) * | 2014-10-23 | 2016-04-28 | Symbiotic Health Inc. | Capsule pour l'administration par voie orale de produits biopharmaceutiques |
CN106617093A (zh) * | 2016-12-30 | 2017-05-10 | 广州新济药业科技有限公司 | 耐酸、稳定的益生菌微胶囊及其制备方法和应用 |
WO2017099559A1 (fr) | 2015-12-10 | 2017-06-15 | Uab "Probiosanus" | Composition et procédé pour augmenter la survie et la stabilisation des bactéries probiotiques (pb) dans des compositions à base de détergent de produits d'hygiène personnelle et domestiques |
CN108245670A (zh) * | 2018-02-08 | 2018-07-06 | 艾伯尔生物科技(重庆)有限公司 | 抗菌蛋白微胶囊的制备方法及其应用 |
CN108902982A (zh) * | 2018-06-25 | 2018-11-30 | 内蒙古农业大学 | 一种益生菌微胶囊冻干粉及其制备方法 |
CN109317066A (zh) * | 2017-08-01 | 2019-02-12 | 无限极(中国)有限公司 | 一种肉豆蔻精油微胶囊及其制备方法和应用 |
CN109482113A (zh) * | 2018-12-26 | 2019-03-19 | 四川三联新材料有限公司 | 一种卷烟湿爆珠干燥前处理的方法 |
US20190192439A1 (en) * | 2015-12-17 | 2019-06-27 | Universidad De Navarra | Microparticles for encapsulating probiotics, obtaining said microparticles and uses thereof |
CN110623066A (zh) * | 2019-08-21 | 2019-12-31 | 厦门益力康生物科技有限公司 | 一种复合益生菌制品及制备方法 |
CN110946287A (zh) * | 2019-11-05 | 2020-04-03 | 中国疾病预防控制中心营养与健康所 | 一种载益生菌的微胶囊的制备方法及由其制得产品和应用 |
WO2021150456A1 (fr) * | 2020-01-24 | 2021-07-29 | International Flavors & Fragrances Inc. | Micro-encapsulation avec une protéine végétale |
CN113854361A (zh) * | 2021-10-08 | 2021-12-31 | 福建技术师范学院 | 一种核壳结构的冻干草莓益生菌奶豆及其制备方法 |
CN113892652A (zh) * | 2021-10-13 | 2022-01-07 | 深圳市华宝生物材料科技有限公司 | 一种油溶性益生菌微胶囊复合冻干粉及其制备方法 |
CN114645004A (zh) * | 2022-05-17 | 2022-06-21 | 微康益生菌(苏州)股份有限公司 | 一种保持功效递送的动物双歧杆菌乳亚种菌剂的制备方法 |
CN114847484A (zh) * | 2022-05-24 | 2022-08-05 | 浙江大学 | 一种负载益生菌的海藻酸盐微胶囊及其制备方法与应用 |
CN115399461A (zh) * | 2022-08-30 | 2022-11-29 | 常熟理工学院 | 一种益生菌缓释果冻及其制备方法和应用 |
CN115769897A (zh) * | 2022-12-16 | 2023-03-10 | 江中药业股份有限公司 | 一种益生菌乳剂及其制备方法 |
CN114711435B (zh) * | 2022-04-06 | 2023-05-09 | 深圳安馨堂生物科技有限公司 | 膳食纤维益生菌组合物及其制备方法 |
CN116076730A (zh) * | 2022-09-13 | 2023-05-09 | 广东益可维生物技术有限公司 | 含有益生元的益生菌微胶囊及其制备方法 |
CN116076731A (zh) * | 2022-09-20 | 2023-05-09 | 湖南营养树生物科技有限公司 | 一种高免疫活力的益生菌制剂及其制备方法 |
CN116098230A (zh) * | 2022-11-10 | 2023-05-12 | 深圳市豆柴宠物用品有限公司 | 包埋益生菌的微胶囊的制备方法及改善宠物肠道菌群的日粮 |
PL443812A1 (pl) * | 2023-02-16 | 2023-07-17 | Politechnika Krakowska im.Tadeusza Kościuszki | Sposób otrzymywania mikrokapsułek zawierających bakterie probiotyczne |
GB2615103A (en) * | 2022-01-27 | 2023-08-02 | Anabio Tech Limited | A method of forming a composition comprising a probiotic micro-encapsulated in a denatured plant protein matrix |
CN117297100A (zh) * | 2023-11-28 | 2023-12-29 | 南昌大学 | 多流体同轴喷雾制备的益生菌微胶囊及其制备方法和应用 |
CN117512795A (zh) * | 2023-11-07 | 2024-02-06 | 合肥芯能相变新材料科技有限公司 | 一种高固含量的小粒径益生菌微胶囊及其应用 |
CN117598396A (zh) * | 2024-01-23 | 2024-02-27 | 山东健源生物科技有限公司 | 一种提高益生菌抗逆性的微胶囊及其制备方法 |
WO2024114679A1 (fr) * | 2022-11-30 | 2024-06-06 | 内蒙古伊利实业集团股份有限公司 | Microcapsule pour libération ciblée dans l'intestin et son procédé de préparation, et composition alimentaire |
-
2014
- 2014-08-06 WO PCT/IB2014/063750 patent/WO2015019307A1/fr active Application Filing
Non-Patent Citations (5)
Title |
---|
AMIN, T. ET AL.: "Microencapsulation - the future of probiotic cultures", JOURNAL OF MICROBIOLOGY, BIOTECHNOLOGY AND FOOD SCIENCES, vol. 3, no. 1, 1 August 2013 (2013-08-01), pages 35 - 43, Retrieved from the Internet <URL:http://www.jmbfs.org/wp-content/uploads/2013/07/jmbfs-0315-amin.pdf> * |
ANDRADE, J.C. ET AL.: "Microencapsulation of probiotic bacteria in alginate-protein mixtures", XVIII INTERNATIONAL CONFERENCE ON BIOENCAPSULATION- PORTO, 1 October 2010 (2010-10-01), PORTUGUL, pages 102, Retrieved from the Internet <URL:http://impascience.eu/bioencapsulation/340_contribution_texts/2010-10-01_P-102.pdf> * |
GBASSI, G.K. ET AL.: "Probiotic encapsulation technology: from microencapsulation to release into the gut", PHARMACEUTICS, vol. 4, 2012, pages 149 - 163, Retrieved from the Internet <URL:http://www.mdpi.com/1999-4923/4/1/149> * |
KLEMMER, K.J. ET AL.: "Synbiot encapsulation employing a pea protein-alginate matrix", MASTER'S THESIS, 2011, Retrieved from the Internet <URL:http://ecommons.usaskca/bitstream/handle/10388/etd-03222011-113052/KarlaKlemmerThesis.pdf> * |
VIDHYALAKSHMI, R. ET AL.: "Encapsulation 'the future of probiotics' - a review", ADVANCES IN BIOLOGICAL RESEARCH, vol. 3-4, 2009, pages 96 - 103, Retrieved from the Internet <URL:http://www.idosi.org/abr/3(3-4)/8.pdf> * |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016065279A1 (fr) * | 2014-10-23 | 2016-04-28 | Symbiotic Health Inc. | Capsule pour l'administration par voie orale de produits biopharmaceutiques |
WO2017099559A1 (fr) | 2015-12-10 | 2017-06-15 | Uab "Probiosanus" | Composition et procédé pour augmenter la survie et la stabilisation des bactéries probiotiques (pb) dans des compositions à base de détergent de produits d'hygiène personnelle et domestiques |
US20190192439A1 (en) * | 2015-12-17 | 2019-06-27 | Universidad De Navarra | Microparticles for encapsulating probiotics, obtaining said microparticles and uses thereof |
US10993915B2 (en) * | 2015-12-17 | 2021-05-04 | Universidad De Navarra | Microparticles for encapsulating probiotics, obtaining said microparticles and uses thereof |
CN106617093A (zh) * | 2016-12-30 | 2017-05-10 | 广州新济药业科技有限公司 | 耐酸、稳定的益生菌微胶囊及其制备方法和应用 |
CN109317066A (zh) * | 2017-08-01 | 2019-02-12 | 无限极(中国)有限公司 | 一种肉豆蔻精油微胶囊及其制备方法和应用 |
CN109317066B (zh) * | 2017-08-01 | 2021-04-27 | 无限极(中国)有限公司 | 一种肉豆蔻精油微胶囊及其制备方法和应用 |
CN108245670B (zh) * | 2018-02-08 | 2021-01-15 | 艾伯尔生物科技(重庆)有限公司 | 抗菌蛋白微胶囊的制备方法及其应用 |
CN108245670A (zh) * | 2018-02-08 | 2018-07-06 | 艾伯尔生物科技(重庆)有限公司 | 抗菌蛋白微胶囊的制备方法及其应用 |
CN108902982A (zh) * | 2018-06-25 | 2018-11-30 | 内蒙古农业大学 | 一种益生菌微胶囊冻干粉及其制备方法 |
CN109482113A (zh) * | 2018-12-26 | 2019-03-19 | 四川三联新材料有限公司 | 一种卷烟湿爆珠干燥前处理的方法 |
CN109482113B (zh) * | 2018-12-26 | 2022-04-26 | 四川三联新材料有限公司 | 一种卷烟湿爆珠干燥前处理的方法 |
CN110623066A (zh) * | 2019-08-21 | 2019-12-31 | 厦门益力康生物科技有限公司 | 一种复合益生菌制品及制备方法 |
CN110946287B (zh) * | 2019-11-05 | 2022-07-08 | 中国疾病预防控制中心营养与健康所 | 一种载益生菌的微胶囊的制备方法及由其制得产品和应用 |
CN110946287A (zh) * | 2019-11-05 | 2020-04-03 | 中国疾病预防控制中心营养与健康所 | 一种载益生菌的微胶囊的制备方法及由其制得产品和应用 |
EP4093211A4 (fr) * | 2020-01-24 | 2024-04-03 | International Flavors & Fragrances Inc. | Micro-encapsulation avec une protéine végétale |
WO2021150456A1 (fr) * | 2020-01-24 | 2021-07-29 | International Flavors & Fragrances Inc. | Micro-encapsulation avec une protéine végétale |
CN113854361A (zh) * | 2021-10-08 | 2021-12-31 | 福建技术师范学院 | 一种核壳结构的冻干草莓益生菌奶豆及其制备方法 |
CN113854361B (zh) * | 2021-10-08 | 2023-12-22 | 福建技术师范学院 | 一种核壳结构的冻干草莓益生菌奶豆及其制备方法 |
CN113892652A (zh) * | 2021-10-13 | 2022-01-07 | 深圳市华宝生物材料科技有限公司 | 一种油溶性益生菌微胶囊复合冻干粉及其制备方法 |
CN113892652B (zh) * | 2021-10-13 | 2023-10-13 | 拓腾华宝(苏州)生物技术有限公司 | 一种油溶性益生菌微胶囊复合冻干粉及其制备方法 |
GB2615103A (en) * | 2022-01-27 | 2023-08-02 | Anabio Tech Limited | A method of forming a composition comprising a probiotic micro-encapsulated in a denatured plant protein matrix |
CN114711435B (zh) * | 2022-04-06 | 2023-05-09 | 深圳安馨堂生物科技有限公司 | 膳食纤维益生菌组合物及其制备方法 |
CN114645004B (zh) * | 2022-05-17 | 2023-02-10 | 微康益生菌(苏州)股份有限公司 | 一种保持功效递送的动物双歧杆菌乳亚种菌剂的制备方法 |
CN114645004A (zh) * | 2022-05-17 | 2022-06-21 | 微康益生菌(苏州)股份有限公司 | 一种保持功效递送的动物双歧杆菌乳亚种菌剂的制备方法 |
CN114847484A (zh) * | 2022-05-24 | 2022-08-05 | 浙江大学 | 一种负载益生菌的海藻酸盐微胶囊及其制备方法与应用 |
CN115399461A (zh) * | 2022-08-30 | 2022-11-29 | 常熟理工学院 | 一种益生菌缓释果冻及其制备方法和应用 |
CN116076730A (zh) * | 2022-09-13 | 2023-05-09 | 广东益可维生物技术有限公司 | 含有益生元的益生菌微胶囊及其制备方法 |
CN116076731A (zh) * | 2022-09-20 | 2023-05-09 | 湖南营养树生物科技有限公司 | 一种高免疫活力的益生菌制剂及其制备方法 |
CN116076731B (zh) * | 2022-09-20 | 2024-04-26 | 湖南营养树生物科技有限公司 | 一种高免疫活力的益生菌制剂及其制备方法 |
CN116098230A (zh) * | 2022-11-10 | 2023-05-12 | 深圳市豆柴宠物用品有限公司 | 包埋益生菌的微胶囊的制备方法及改善宠物肠道菌群的日粮 |
WO2024114679A1 (fr) * | 2022-11-30 | 2024-06-06 | 内蒙古伊利实业集团股份有限公司 | Microcapsule pour libération ciblée dans l'intestin et son procédé de préparation, et composition alimentaire |
CN115769897A (zh) * | 2022-12-16 | 2023-03-10 | 江中药业股份有限公司 | 一种益生菌乳剂及其制备方法 |
CN115769897B (zh) * | 2022-12-16 | 2023-10-27 | 江中药业股份有限公司 | 一种益生菌乳剂及其制备方法 |
PL443812A1 (pl) * | 2023-02-16 | 2023-07-17 | Politechnika Krakowska im.Tadeusza Kościuszki | Sposób otrzymywania mikrokapsułek zawierających bakterie probiotyczne |
CN117512795A (zh) * | 2023-11-07 | 2024-02-06 | 合肥芯能相变新材料科技有限公司 | 一种高固含量的小粒径益生菌微胶囊及其应用 |
CN117512795B (zh) * | 2023-11-07 | 2024-04-30 | 合肥芯能相变新材料科技有限公司 | 一种高固含量的小粒径益生菌微胶囊及其应用 |
CN117297100B (zh) * | 2023-11-28 | 2024-04-26 | 南昌大学 | 多流体同轴喷雾制备的益生菌微胶囊及其制备方法和应用 |
CN117297100A (zh) * | 2023-11-28 | 2023-12-29 | 南昌大学 | 多流体同轴喷雾制备的益生菌微胶囊及其制备方法和应用 |
CN117598396B (zh) * | 2024-01-23 | 2024-04-05 | 山东健源生物科技有限公司 | 一种提高益生菌抗逆性的微胶囊及其制备方法 |
CN117598396A (zh) * | 2024-01-23 | 2024-02-27 | 山东健源生物科技有限公司 | 一种提高益生菌抗逆性的微胶囊及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015019307A1 (fr) | Microcapsules contenant des probiotiques et leurs méthodes de fabrication | |
Wang et al. | Entrapment, survival and release of Bifidobacterium adolescentis within chickpea protein-based microcapsules | |
Razavi et al. | Microencapsulating polymers for probiotics delivery systems: Preparation, characterization, and applications | |
Anal et al. | Recent advances in microencapsulation of probiotics for industrial applications and targeted delivery | |
Silva et al. | Symbiotic microencapsulation to enhance Lactobacillus acidophilus survival | |
DK1667696T3 (en) | PROBIOTIC STORAGE AND SUBMISSION | |
Kanmani et al. | Cryopreservation and microencapsulation of a probiotic in alginate-chitosan capsules improves survival in simulated gastrointestinal conditions | |
Khan et al. | Development of extrusion-based legume protein isolate–alginate capsules for the protection and delivery of the acid sensitive probiotic, Bifidobacterium adolescentis | |
Islam et al. | Microencapsulation of live probiotic bacteria | |
KR101902035B1 (ko) | 산성 분해로부터 미생물 세포의 보호 | |
Li et al. | Construction of multilayer alginate hydrogel beads for oral delivery of probiotics cells | |
Haghshenas et al. | Effect of addition of inulin and fenugreek on the survival of microencapsulated Enterococcus durans 39C in alginate-psyllium polymeric blends in simulated digestive system and yogurt | |
Damodharan et al. | Co-encapsulation of lactic acid bacteria and prebiotic with alginate-fenugreek gum-locust bean gum matrix: Viability of encapsulated bacteria under simulated gastrointestinal condition and during storage time | |
AU2012210575A1 (en) | Protection of microbial cells from acidic degradation | |
Wang et al. | Encapsulation of Bifidobacterium adolescentis cells with legume proteins and survival under stimulated gastric conditions and during storage in commercial fruit juices | |
Varankovich et al. | Survival of probiotics in pea protein-alginate microcapsules with or without chitosan coating during storage and in a simulated gastrointestinal environment | |
Kailasapathy | Microencapsulation for gastrointestinal delivery of probiotic bacteria | |
WO2011122934A2 (fr) | Biocapsule et procédé associé | |
Mitsuwan et al. | Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli | |
Aghajania et al. | Microencapsulation of probiotics in yogurt: A Review | |
Goderska et al. | An in vitro gastrointestinal model to evaluate the tolerance of encapsulated Lactobacillus and Lactococcus strains with synbiotic containing lactobionic acid via lyophilization technique to harsh gastric conditions during storage time | |
AU2004275438B2 (en) | Probiotic storage and delivery | |
Song et al. | Encapsulation of Bacillus polyfermenticus SCD with alginate-methylcellulose and evaluation of survival in artificial conditions of large intestine | |
Mirzapour-Kouhdasht et al. | Lactobacillus acidophilus NCFM preservation through entrapment in soy protein isolate: Persian gum complex coacervates under gastrointestinal conditions in vitro | |
Jantarathin | INCREASING VIABILITY OF PROBIOTIC BACTERIA CO-ENCAPSULATED WITH PREBIOTIC FOR DISEASE RESISTANCE IN WHITE SHRIMP Litopenaeus vannamei |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14834072 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14834072 Country of ref document: EP Kind code of ref document: A1 |